Literature DB >> 32712186

Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress.

Marcelo F Lopez1, Sarah E Reasons2, Benjamin A Carper3, Tracy L Nolen3, Rick L Williams3, Howard C Becker4.   

Abstract

The comorbidity between alcohol use disorder and post-traumatic stress disorder represents a serious health care burden with few effective treatment options. The current study was designed to evaluate the effect of an alpha 1 receptor antagonist (doxazosin) and a novel anticonvulsant (zonisamide) in a model of alcohol (ethanol) dependence and stress exposure. The main dependent variable was voluntary ethanol intake in mice that experienced chronic intermittent ethanol (CIE) exposure and forced swim stress (FSS) alone, and in combination. Adult male and female C57BL/6J mice had access to a single bottle of 15% (v/v) ethanol for 1-hr in the home cage, 3-hr into the dark phase of the light/dark cycle. Once stable ethanol intake was established (~4 weeks), mice were separated into four groups (CTL, CIE, FSS, CIE + FSS). Mice in the FSS condition received 10-min FSS exposure 4-hr prior to drinking sessions (remaining mice were not disturbed). During baseline and the first two test cycles, all mice received vehicle (saline) injections (IP) 30-min before ethanol access. As previously observed, FSS increased ethanol drinking in dependent (CIE-exposed) mice but not in nondependent control (CTL) mice. In the following test cycles mice were evaluated for ethanol intake after administration of doxazosin, zonisamide or their combination. Results indicated that the three doses of doxazosin evaluated significantly reduced voluntary ethanol intake in all mice. Zonisamide had a more modest effect and may require a more prolonged treatment regime. The combined administration of both compounds was not more effective than each drug alone. This study suggests that doxazosin is reliable at reducing voluntary ethanol intake in mice independently of their history of ethanol dependence and stress exposure. Published by Elsevier Inc.

Entities:  

Keywords:  Doxazosin; Ethanol dependence; Mouse; Stress; Zonisamide

Year:  2020        PMID: 32712186      PMCID: PMC7719616          DOI: 10.1016/j.alcohol.2020.07.005

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  41 in total

1.  Probable Posttraumatic Stress Disorder in the US Veteran Population According to DSM-5: Results From the National Health and Resilience in Veterans Study.

Authors:  Blair E Wisco; Brian P Marx; Mark W Miller; Erika J Wolf; Natalie P Mota; John H Krystal; Steven M Southwick; Robert H Pietrzak
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

2.  Doxazosin treatment for posttraumatic stress disorder.

Authors:  Joop De Jong; Prudence Wauben; Irma Huijbrechts; Hans Oolders; Judith Haffmans
Journal:  J Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.153

3.  Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice.

Authors:  Marcelo F Lopez; Howard C Becker
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  Effects of zonisamide in the treatment of alcohol dependence.

Authors:  Gabriel Rubio; Francisco López-Muñoz; Francisco Ferre; Isabel Martínez-Gras; Guillermo Ponce; José M Pascual; Miguel A Jiménez-Arriero; Cecilio Alamo
Journal:  Clin Neuropharmacol       Date:  2010 Sep-Oct       Impact factor: 1.592

5.  Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking.

Authors:  Xiang Yang Zhang; Therese A Kosten
Journal:  Biol Psychiatry       Date:  2005-05-15       Impact factor: 13.382

6.  Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats.

Authors:  A D Lê; Douglas Funk; Walter Juzytsch; Kathleen Coen; Brittany M Navarre; Carlo Cifani; Yavin Shaham
Journal:  Psychopharmacology (Berl)       Date:  2011-02-12       Impact factor: 4.530

7.  The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats.

Authors:  Meghan L O'Neil; Lauren E Beckwith; Carrie L Kincaid; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2012-07-03       Impact factor: 3.455

8.  Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake.

Authors:  Janice C Froehlich; Brett J Hausauer; David L Federoff; Stephen M Fischer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-06-03       Impact factor: 3.455

9.  Modeling associations between posttraumatic stress symptoms and substance use.

Authors:  Paige Ouimette; Jennifer P Read; Michael Wade; Vanessa Tirone
Journal:  Addict Behav       Date:  2009-08-19       Impact factor: 3.913

Review 10.  Nature and Treatment of Comorbid Alcohol Problems and Post Traumatic Stress Disorder Among American Military Personnel and Veterans.

Authors:  John P Allen; Eric F Crawford; Harold Kudler
Journal:  Alcohol Res       Date:  2016
View more
  3 in total

Review 1.  Assessing negative affect in mice during abstinence from alcohol drinking: Limitations and future challenges.

Authors:  Solal Bloch; Katherine M Holleran; Thomas L Kash; Elena M Vazey; Jennifer A Rinker; Christina L Lebonville; Krysten O'Hara; Marcelo F Lopez; Sara R Jones; Kathleen A Grant; Howard C Becker; Patrick J Mulholland
Journal:  Alcohol       Date:  2022-02-15       Impact factor: 2.405

2.  Dynorphin/Kappa Opioid Receptor Activity Within the Extended Amygdala Contributes to Stress-Enhanced Alcohol Drinking in Mice.

Authors:  Harold L Haun; Christina L Lebonville; Matthew G Solomon; William C Griffin; Marcelo F Lopez; Howard C Becker
Journal:  Biol Psychiatry       Date:  2022-01-10       Impact factor: 12.810

Review 3.  Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Authors:  Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray
Journal:  Drugs       Date:  2022-02-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.